Drug Profile
CNDO 109
Alternative Names: Allogeneic tumour activated natural killer lymphocytes; CNDO-102; CNDO-109; CNDO-109-AANK Cells; CNDO-109-activated allogeneic NK cell therapy; CNDO-109-NKLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator University College London
- Developer Fortress Biotech
- Class Antineoplastics; Biological intercellular signalling peptides and proteins; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Multiple myeloma; Solid tumours
Most Recent Events
- 22 Feb 2023 Discontinued - Phase-I/II for Acute myeloid leukaemia (Prevention of relapse) in USA (IV)
- 22 Feb 2023 Discontinued - Preclinical for Multiple myeloma in USA (IV)
- 04 Apr 2019 Coronado Biosciences completes a phase I/II trial for Acute myeloid leukaemia in the USA